SCHEMBL4235398

SCHEMBL4235398

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(C(N)=O)cc2C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.55
TAS1R3 Q7RTX0 5/20 0.48
TAS1R1 Q7RTX1 5/20 0.48
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LTA4H P09960 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
F7 P08709 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233459 0.86 PKM (0.57) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4238631 0.86 MEN1 (0.52) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL4236704 0.86 PKM (0.66) PKMTAS1R3TAS1R1CYP2C9CYP2C19
Ammonia Solution, Strong SCHEMBL4233431 0.85 PKM (0.56) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4236717 0.85 PKM (0.54) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4228260 0.84 PKM (0.54) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4229112 0.83 PKM (0.57) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL4236662 0.83 PKM (0.50) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL4242067 0.81 PKM (0.48) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4686909 0.81 HDAC1 (0.55) ALDH1A1MEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.